



## **Intravenous immunoglobulin induces IL-4 in human basophils by signaling through 1 surface-bound IgE**

Caroline C Galeotti, Emmanuel Stephen-Victor, Anupama Karnam, Mrinmoy Das, Laurent Gilardin, Mohan S Maddur, Sandra C Wymann, Cédric V Vonarburg, Alain Chevailler, Jordan D Dimitrov, et al.

### **► To cite this version:**

Caroline C Galeotti, Emmanuel Stephen-Victor, Anupama Karnam, Mrinmoy Das, Laurent Gilardin, et al.. Intravenous immunoglobulin induces IL-4 in human basophils by signaling through 1 surface-bound IgE. *Journal of Allergy and Clinical Immunology*, 2019, 144 (2), pp.524-535.e8. 10.1016/j.jaci.2018.10.064 . hal-02284256

**HAL Id: hal-02284256**

**<https://hal.sorbonne-universite.fr/hal-02284256>**

Submitted on 11 Sep 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE**

**Caroline Galeotti, MD, PhD<sup>1,2</sup>, Emmanuel Stephen-Victor, PhD<sup>1,\*</sup>, Anupama Karnam, MSc<sup>1,\*</sup>, Mrinmoy Das, PhD<sup>1</sup>, Laurent Gilardin, MD<sup>1,3</sup>, Mohan S Maddur, DVM, PhD<sup>1,4</sup>, Sandra Wymann, PhD<sup>5</sup>, Cédric Vonarburg, PhD<sup>5</sup>, Alain Chevailler, MD, PhD<sup>6</sup>, Jordan D Dimitrov, PhD<sup>1,4</sup>, Olivier Benveniste, MD<sup>3,7</sup>, Pierre Bruhns, PhD<sup>8,9</sup>, Srinivasa Kaveri, DVM, PhD<sup>1,4</sup>, Jagadeesh Bayry, DVM, PhD<sup>1,4</sup>**

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale; Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique; Sorbonne Université, Paris, F-75006, France

<sup>2</sup>Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires rares et des Amyloses, CHU de Bicêtre, le Kremlin Bicêtre, F-94270, France

<sup>3</sup>Département de Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, F-75013, France.

<sup>4</sup>Université Paris Descartes, Sorbonne Paris Cité, Paris, F-75006, France

<sup>5</sup>Research Department, CSL Behring AG, 3014 Bern, Switzerland

<sup>6</sup>Laboratoire d'Immunologie et d'Allergologie; CHU d'Angers; Université d'Angers; INSERM Unité 1232; LabEx IGO "Immuno-Graft-Onco", Angers, F-49933, France

<sup>7</sup>Sorbonne Université, Institut National de la Santé et de la Recherche Médicale Unité 974, Paris, F-75013, France.

<sup>8</sup>Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France

<sup>9</sup>INSERM Unité 1222, Paris, France

\* Equally contributed

**Correspondence to:** Jagadeesh Bayry, Institut National de la Santé et de la Recherche Médicale Unité 1138, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Médecine, Paris, F-75006, France. Tel: 00 33 1 44 27 82 03; Fax: 00 33 1 44 27 81 94  
E-mail: [jagadeesh.bayry@crc.jussieu.fr](mailto:jagadeesh.bayry@crc.jussieu.fr)

**Sources of Funding:** Supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie, Université Paris Descartes and CSL Behring, Switzerland. CG is a recipient of fellowship from La Fondation pour la Recherche Médicale (FDM20150633674), France; ESV and AK are recipient of fellowships from Indo-French Center for Promotion of Advanced Research (CEFIPRA).

**Conflicts of Interests statement**

The work is supported in part by research grant from CSL Behring, Switzerland. S Wymann and C Vonarburg are employees of CSL Behring, Switzerland.

**Total word count: 3631**

**Abstract: 249**

**ABSTRACT**

**BACKGROUND:** Therapeutic normal immunoglobulin G or intravenous immunoglobulin (IVIG) exerts anti-inflammatory effects via several mutually nonexclusive mechanisms. Recent data in mouse models of autoimmune diseases suggest that IVIG induces IL-4 in basophils by enhancing IL-33 in SIGN-R1<sup>+</sup> innate cells. However, translational insight on these data is lacking.

**OBJECTIVE:** We sought to investigate the effect of IVIG on human basophil functions.

**METHODS:** Isolated circulating basophils from the healthy donors were cultured in the presence of IL-3, IL-33, GM-CSF, TSLP or IL-25. The effect of IVIG, F(ab')<sub>2</sub> and Fc fragments of IVIG was examined on the expression of various surface molecules, phosphorylation of Syk, induction of cytokines, and histamine release. Phenotype of basophils was also analyzed from IVIG-treated myopathy patients. Approaches such as depletion of anti-IgE-reactivity from IVIG, blocking antibodies or inhibitors were used to investigate the mechanisms.

**RESULTS:** We report that IVIG directly induces activation of IL-3-primed human basophils, but IL-33 and other cytokines were dispensable for this effect. The activation of basophils by IVIG led to enhanced expression of CD69 and secretion of IL-4, IL-6 and IL-8. IVIG-treated myopathy patients displayed enhanced expression of CD69 on the basophils. Syk pathway is implicated in these functions of IVIG and were mediated via F(ab')<sub>2</sub> fragments. Mechanistically, IVIG induced IL-4 in human basophils by interacting with basophil surface-bound IgE but independent of FcγRII, type II Fc receptors, C-type lectin receptors and Siglecs.

**CONCLUSION:** These results uncovered a pathway of promoting Th2 response by IVIG through direct interaction of IgG with human basophils.

**Key Messages**

- IVIG induces activation and secretion of IL-4, IL-6 and IL-8 in IL-3-primed human basophils but unlike mice IL-33 was dispensable
- IVIG induces human basophil activation via F(ab')<sub>2</sub> fragments but independent of FcγRII, C-type lectin receptors, type II Fc receptors and Siglecs
- Basophil activation by IVIG is mediated by a fraction of IgG that signals through basophil surface-bound IgE and the Syk pathway

**Capsule summary**

Therapeutic normal IgG (IVIG) activates human basophils through direct interaction with basophil surface-bound IgE, and by IL-3- and Syk-dependent mechanisms to promote Th2 responses in the context of therapy of autoimmune diseases.

**Key words**

FcεRI, Anti-IgE IgG, Antisynthetase syndrome, Polymyositis, Dermatomyositis, DC-SIGN, DCIR, FcγRIIB

**Abbreviations**

DCIR: Dendritic cell immunoreceptor  
DC-SIGN: dendritic cell-specific ICAM-3-grabbing nonintegrin  
FcεRI: Fc epsilon type 1 receptor, high affinity IgE receptor  
FcγR: Fc gamma receptor  
FcγRIIA: Fc gamma type 2 receptor A  
FcγRIIB: Fc gamma type 2 receptor B  
HSA: Human serum albumin  
IVIG: Intravenous immunoglobulin  
SIGN-R1: SIGN- related 1  
SYK: Spleen tyrosine kinase

**INTRODUCTION**

Intravenous immunoglobulin (IVIG) is one of the widely used immunotherapeutic molecules for the treatment of diverse autoimmune and systemic inflammatory diseases.<sup>1-4</sup> High-dose (1-2g/kg) IVIG therapy exerts anti-inflammatory effects by several mutually non-exclusive mechanisms including inhibition of the activation of innate immune cells, effector T (Th1, Th17) and B cells, suppression of complement pathway, neutralization of inflammatory cytokines and pathogenic antibodies, and expansion of regulatory T cells. These actions of IVIG implicate both Fc- and F(ab')<sub>2</sub> fragments.<sup>5,6</sup>

Basophils are one of the rare granulocytes. They express various receptors to sense the signals including FcεRI, a high affinity receptor for IgE, toll-like receptors and cytokine receptors such as IL-3 receptor (CD123), IL-33 receptor (IL-33R) and thymic stromal lymphopoietin (TSLP) receptor. Activated basophils secrete several cytokines including IL-4, IL-8 and IL-6, and regulate Th2 polarization, immunoglobulin synthesis and class-switch in B cells.<sup>7,8</sup>

Recent results from experimental models of systemic inflammatory and autoimmune diseases suggest that the anti-inflammatory effects of IVIG are mediated via basophils by a two-step process.<sup>9</sup> IL-33 produced by SIGN-R1<sup>+</sup> innate cells upon interaction with Fc-α(2,6)-sialic acid linkages, activates basophils via IL-33R to induce IL-4. The basophil-derived IL-4 enhances the expression of inhibitory FcγRIIB on effector macrophages<sup>9</sup> thus adding onto the previously known function of basophil-derived IL-4 in programming anti-inflammatory macrophages.<sup>10</sup> However, translational insight on these data is lacking. In particular, DC-SIGN (human orthologue of SIGN-R1)-positive human innate cells did not produce IL-33 when exposed to IVIG indicating that the proposed pathway of basophil activation by IVIG does not apply to humans.<sup>11</sup> When patients are infused with high-dose

120 IVIG, the IgG theoretically interacts with every component of the immune system.  
121 Therefore, it is most likely that IVIG modulates human basophils through direct interaction  
122 rather than indirect pathway of DC-SIGN-dependent IL-33.

123 In line with our proposition, we report that IVIG directly induces the activation of human  
124 basophils and secretion of IL-4, IL-6 and IL-8 through interaction with basophil surface-  
125 bound IgE, and by IL-3- and Syk-dependent mechanisms. These functions of IVIG were  
126 mediated via F(ab')<sub>2</sub> fragments and were independent of IL-33, FcγRII, type II FcRs, C-  
127 type lectin receptors and Siglecs. Basophils from IVIG-treated myopathy patients also  
128 displayed enhanced expression of activation marker CD69. In the context of systemic  
129 autoimmune and inflammatory diseases, these results thus provide a unique pathway of  
130 promoting Th2 response by IVIG through direct interaction of IgG with human basophils.

131

## **METHODS**

### **Preparations of IVIG**

Sandoglobulin® (CSL Behring, Switzerland) was dialyzed against a large volume of PBS three times followed by RPMI-1640 at 4°C for 18 hours to remove the stabilizing agents.

F(ab')<sub>2</sub> fragments of IVIG were prepared by pepsin digestion (2% wt/wt; Sigma Aldrich) followed by chromatography on a protein G Sepharose column (Pharmacia). Fc fragments of IVIG were prepared by papain digestion (papain-coupled beads, Life Technologies) followed by protein A Sepharose column chromatography and size-exclusion chromatography. End purification was performed by chromatography on an IgG-CH1 column (Life Technologies). The purity of F(ab')<sub>2</sub> and Fc fragments were confirmed by SDS-PAGE.

### **Isolation and culture of basophils**

Basophils were isolated from the PBMC of healthy donors buffy bags (Centre Necker-Cabanel, EFS, Paris, INSERM-EFS ethical permission N°12/EFS/079 and N°18/EFS/033) by using basophil isolation kit II (Miltenyi Biotec) and autoMACS® (Miltenyi Biotec). The purity of basophils based on the expression of FcεRI and CD123 was ≈97%.

To investigate the effect of IVIG on IL-3-primed basophils, cells (0.1x10<sup>6</sup>/well/200 μL) were cultured in 96 well U-bottomed plate either alone in serum-free X-VIVO 15 medium; or with IL-3 (100 ng/mL, ImmunoTools); or with IL-3 plus IVIG (25 mg/mL) or human serum albumin (HSA, 10 mg/mL, LFB, France) or F(ab')<sub>2</sub> fragments (16 mg/mL) or Fc fragments (9 mg/mL) for 24 hours.

To explore the effect of other cytokines on IVIG-mediated regulation of basophils, cells were cultured with individual cytokines (IL-33:1 ng/mL, GM-CSF:10 ng/mL, IL-25:10

ng/mL or TSLP:100 ng/mL, all from ImmunoTools), or cytokines plus IVIG for 24 hours. Also, basophils were sequentially stimulated with IL-3 and IL-33 for one hour each and cultured with IVIG or HSA for additional 22 hours.

For blocking experiments, basophils were stimulated with IL-3 for 2 hours followed by incubation with blocking MAbs to FcγRIIB (Clone:2B6 N<sub>297</sub>D; 10 μg/mL), FcγRIIA (Clone:IV.3; 10 μg/mL) or isotype control MAbs for 1 hour and cultured with IVIG for additional 21 hours.

To investigate the implication of Syk pathway, basophils were stimulated with IL-3 for 2 hours followed by incubation with Syk inhibitor, R406 (5 μmol, InvivoGen) or DMSO for 1 hour and cultured with IVIG for up to 24 hours.

Basophils were analyzed for the expression of various markers by flow cytometry (LSR II, BD Biosciences) using fluorochrome-conjugated MAbs. Phosphorylation of Syk was analyzed by using cell signaling buffer set A (Miltenyi Biotec). Data were analyzed by BD FACS DIVA (BD Biosciences) and Flowjo (FlowJo LLC). Cell-free culture supernatants were used for the analysis of histamine and cytokines.

#### **Depletion of IgE-reactive IgG from IVIG**

Plasma IgE (5.427 mg/mL) from a patient with secreted IgE-myeloma was immobilized on a CNBr-activated Sepharose 4B (Sigma-Aldrich). IVIG was loaded (60 mg/mL) on to IgE Sepharose column and was incubated on a rotator at room temperature for 4 hours. The flow-through fraction was collected. Following elution of column-bound IgG, the flow-through IgG was again passed through the IgE Sepharose column for two more times. The IgG in the flow-through fraction was concentrated and the concentration was determined by spectrophotometer (NanoDrop Technologies).

IVIG depleted of anti-IgE-reactivity (25 mg/mL) was added to IL-3-primed basophils (0.1x10<sup>6</sup>/well/200 µL) as described earlier for 24 hours.

#### **Analysis of basophils from myopathy patients**

Heparinized blood from seven myopathy patients (45.71±5.9 years; five men; ethical approval from CPP-Ile-de-France VI, Groupe Hospitalier Pitié-Salpêtrière, Paris) were collected before and 2-5 days post-IVIG treatment (2 g/kg). CD69 on the basophils (FcεRIα<sup>+</sup>CD203c<sup>+</sup>) was analyzed by flow cytometry. Due to low number, basophils were analyzed only in five patients (two patients with antisynthetase syndrome and one each with polymyositis, immune-mediated necrotizing myopathy or dermatomyositis).

#### **Antibodies for flow cytometry and functional assays**

The details are provided in the supplementary file (in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org))

#### **Measurement of cytokines and histamine**

IL-4, IL-6 and IL-8 were analyzed in culture supernatants by ELISA (ELISA Ready-SET-Go, eBioscience Affymetrix). Histamine was measured in culture supernatants by histamine EIA kit (Bertin Pharma).

#### **RNA isolation and real-time quantitative RT-PCR**

RNeasy Micro Kit (Qiagen) was used for RNA isolation from resting basophils, cells treated with IL-3 or IL-3 plus IVIG for three hours. Additionally, basophils were also treated with Syk inhibitor for one hour prior to stimulation with IL-3 plus IVIG. cDNA was synthesized using iScript<sup>TM</sup> cDNA synthesis kit (Bio-Rad). qRT-PCR was done using TaqMan<sup>TM</sup> Universal Master Mix II, with UNG (Applied Biosystems<sup>TM</sup>) and IL-4

200 expression was measured using TaqMan Gene Expression Assays (Applied Biosystems™)  
201 #Hs00174122\_m1 (IL-4), #Hs02786624\_g1 (GAPDH).

202 **Statistical analysis:**

203 Statistical analysis was performed by Prism 6 GraphPad Software. One-way analysis of  
204 variance (with Tukey's multiple comparison tests or Dunnet's multiple comparison tests),  
205 and two-way Mann Whitney were used to determine the statistical significance.

206

207

## RESULTS

### IVIG induces activation and cytokine secretion in IL-3-primed basophils

We first probed the effect of IVIG on resting basophils. However, IVIG did not modify either phenotype or functions of resting basophils based on the analysis of CD69 (Fig 1, A and B) and secretion of IL-4, IL-6 and IL-8 (Fig 1, C) indicating that resting basophils are not the targets for IVIG.

We then investigated whether IVIG modulates primed basophils, in particular IL-3, the major basophil priming cytokine. We found that under IL-3-priming, IVIG significantly enhanced CD69, an activation marker of basophils (Fig 1, D). On the other hand, the expression of CD13, CD62L, CD123 and CD203c (Fig E1, in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)), degranulation-associated markers CD63 (Fig 1, E) and CD107a (Fig E2, A and B), and histamine concentrations in the supernatants (Fig E2, C) were not significantly altered by IVIG.

Further, IVIG significantly enhanced IL-4, IL-6 and IL-8 secretion by IL-3-primed basophils (Fig 1, F). qRT-PCR analysis also confirmed *il4* induction by IVIG (Fig E3). Equimolar concentrations of HSA, used as a protein control for IVIG did not significantly alter the expression of basophil markers and cytokine production, thus confirming that IVIG could directly induce activation of IL-3-primed basophils without leading to degranulation. Preliminary exploration in IVIG-treated myopathy patients also confirmed enhancement of CD69 on the basophils of four out of five patients analyzed (Fig 1, G).

### IL-33 and other cytokines are dispensable for the activation of basophils by IVIG

Because IL-4 secretion by basophils in mouse requires an IL-33 stimulation following IVIG infusion,<sup>9</sup> we wondered if IL-33 could, like IL-3, prime human basophils to be activated by IVIG. Unlike IL-3 (Fig 1, D-F), only a marginal increase in the expression of

CD69 on basophils (Fig 2, *A* and *B*) or their cytokine production (Fig 2, *C*) was observed following IL-33 stimulation of basophils at a dose equivalent of that induced in IVIG-treated patients.<sup>11,12</sup> Despite enhancement of IL-33R expression by IL-3 (Fig E4), IL-33 when used in combination with IL-3 did not exert either synergistic or additive effect on IVIG-induced basophil activation (Fig 2, *D* and *E*). These results hence do not support a major role for IL-33 in priming human basophils towards IVIG responsiveness. Other cytokines like IL-25, TSLP and GM-CSF also had no significant effect on the IVIG-induced basophil activation (Fig E5). Altogether these results (Fig 1 and 2) indicate that IVIG induces IL-4 in human basophils, as had been described in mouse model.<sup>9</sup> Unlike mice however, IVIG appears to have a direct effect on human basophils leading to IL-4 secretion, as long as basophils were primed with IL-3.

#### **IVIG induces basophil activation via F(ab')<sub>2</sub> fragments while type II FcRs, C-type lectin receptors and Siglecs are dispensable**

We aimed at identifying the receptors that mediate basophil activation. Recently, “type II FcRs” that include DC-SIGN and CD23 that interact with Fc-domain in the closed conformation, were reported to mediate anti-inflammatory actions of IVIG.<sup>13</sup> But human basophils were negative for CD23 and DC-SIGN<sup>14</sup> thus ruling out their involvement in IVIG-induced basophil activation (Fig 3, *A*).

As Fc- $\alpha$ (2,6)-sialic acid linkages could be recognized by various Siglecs, we investigated their implication in the cross-talk between IVIG and basophils. Siglec-2 (CD22) and Siglec-14 specifically recognize  $\alpha$ (2,6)-sialic acid linkages. However, both resting and IL-3-primed basophils were negative for CD22 (Fig 3, *B*). In addition, basophils did not express Siglec-3, -5/14, -7 and -8 (Fig E6), which all possess some affinity for (2,6)-sialic acid linkages. Siglec-10 was previously reported to be undetectable on basophils.<sup>15</sup>

DCIR, a C-type lectin receptor has been reported to recognize  $\alpha(2,6)$ -sialic acid linkages of IgG.<sup>16</sup> Nearly 80% of the steady-state and 95% of the IL-3-primed basophils express DCIR, but IVIG did not alter this expression (Fig 3, *C* and *D*). Importantly, IVIG did not induce activation of the resting basophils (Fig 1, *A-C*) despite these cells express DCIR, thus indirectly ruling out the role of DCIR in IVIG-induced basophil activation.

The lack of involvement of known receptors for  $\alpha(2,6)$ -sialic acid-linkages point toward a role for F(ab')<sub>2</sub>-domain rather than Fc-portion of IVIG on basophil activation. Accordingly, F(ab')<sub>2</sub> fragments of IVIG but not Fc fragments significantly enhanced CD69 (Fig 3, *E* and *F*) and the production of both IL-4 and IL-8 (Fig 3, *G* and *H*).

#### **Basophil activation by IVIG is mediated by a fraction of IgG that signals through basophil surface-bound IgE**

Classically, IL-3 has been known for its critical role in favouring basophil-sensitization by IgE for augmented Fc $\epsilon$ RI-mediated signals and secretion of various inflammatory mediators.<sup>17-19</sup> Our data demonstrates that IL-3-priming is also a pre-requisite for the IVIG-induced basophil activation. IVIG significantly down-regulated Fc $\epsilon$ RI on IL-3-primed basophils (Fig 4, *A* and *B*), suggesting that IVIG binding to Fc $\epsilon$ RI and/or to Fc $\epsilon$ RI-bound IgE triggered the internalization of Fc $\epsilon$ RI. As expected, basophils displayed IgE on their surface (Fig 4, *C* and *D*) and IL-3 treatment dramatically licensed basophils to bind IVIG (Fig 4, *E* and *F*). However, incubation of basophils with additional IgE, did not alter the intensity of basophil-surface IgE indicating that all Fc $\epsilon$ RI on the basophils are already saturated by IgE. These arguments point out that IVIG induces activation of basophils possibly via signalling through basophil Fc $\epsilon$ RI-bound IgE rather than Fc $\epsilon$ RI. Importantly, depletion of anti-IgE-reactivity within IVIG suppressed the ability of IVIG to activate IL-

3-primed basophils, revealed by the poor increase in CD69 expression (Fig 4, *G* and *H*), and the abrogation of secretion of IL-4 and IL-8 (Fig 4, *I*).

# **Activating and inhibitory CD32/FcγRII are dispensable for the regulation of basophil activation by IVIG**

By interacting with Fc-domain of IgG, FcγRs influence the activation of immune cells.<sup>20</sup> Human basophils mainly express FcγRIIA and FcγRIIB.<sup>21</sup> While FcγRIIA is an activating receptor, signaling via FcγRIIB inhibits activation of immune cells.<sup>20</sup> Therefore, we wondered whether IVIG-induced basophil activation is regulated by FcγRII.

First, we analyzed the expression pattern of FcγRII on basophils. IL-3 although enhanced the expression of both FcγRIIA and FcγRIIB, a non-significant trend towards reduced expression of both the receptors was observed upon IVIG stimulation (Fig 5, *A* and *B*). Thus, unlike monocytes and B cells of chronic inflammatory demyelinating polyneuropathy patients that showed enhanced FcγRIIB expression upon IVIG therapy,<sup>22</sup> the ratio of intensity of expression of FcγRIIB to FcγRIIA remains unchanged on IVIG-treated basophils. Our data are similar to that observed with splenic macrophages of IVIG-treated adult immune thrombocytopenia patients.<sup>23</sup>

High-affinity Rabbit Anti-Human-IgE (RAHE) IgG was shown to negatively regulate IgE-induced activation of human basophils by co-engaging FcγRIIB.<sup>21</sup> Hence, we asked whether FcγRIIB blockade would enhance the activation of basophils by IVIG. However, IVIG-induced activation of basophils was not significantly altered upon FcγRIIB blockade (Fig 5, *C* and *D*).

As FcγRIIA signalling induces activation of immune cells,<sup>20</sup> we explored if IVIG-induced basophil activation implicates co-engagement with this receptor. But FcγRIIA blockade had no repercussion on the IVIG-induced expression of CD69 and cytokines (Fig 5, *E* and

*F*), demonstrating that FcγRII (activating or inhibitory) has no significant role in the regulation of human basophil function by IVIG.

### **Syk pathway is critical for the basophil activation by IVIG**

FcεRI-mediated activation of human basophils in vitro requires both priming by IL-3 and the kinase Syk that is recruited to the FcεRI signalling complex.<sup>17-19</sup> Noticeably, IL-3-mediated down-stream signalling has also been reported to be Syk-dependent.<sup>24,25</sup> Freshly isolated basophils showed basal phosphorylation of Syk (pSyk). In line with the fact that IL-3 induces rapid phosphorylation of Syk, we found that IL-3 significantly enhanced pSyk. A treatment with IL3 plus IVIG resulted in similar pSyk induction (Fig 6, A and B). Further, inhibition of Syk, using inhibitor R406, abrogated IVIG-induced enhancement of CD69 (Fig 6, C and D) and production of IL-4 and IL-8 (Fig 6, E). qRT-PCR also confirmed abrogation of IVIG-induced *il4* following Syk inhibition (Fig E7). Altogether these data suggest that IVIG, due to IgE reactivity it contains, induces activation of IL-3-primed basophil by signalling through FcεRI-bound IgE.

**DISCUSSION**

Despite having pathogenic roles in various diseases,<sup>8,26,27</sup> recent evidence from mouse also suggests that basophils are central to the anti-inflammatory effects of IVIG thus providing an intriguing new function to these rare immune cells.<sup>9</sup> However, this proposed role of basophils in mediating the therapeutic benefits of IVIG could not be reproduced in another report.<sup>28</sup> It is important to note that both studies have employed anti-FcεRI MAb MAR-1 to deplete the basophils and this antibody has been reported to deplete FcεRI-positive DCs as well.<sup>29,30</sup> Also, as compared to mouse, human basophils display distinct features.<sup>8,31,32</sup> Therefore, the effect of IVIG on basophil functions is far from clear. Notably, data from human raise an alternative paradigm that IVIG might modulate basophil functions directly rather than indirect IL-33-dependent pathway.<sup>11</sup>

Human basophils express receptors for various cytokines. In addition to IL-33, mainly produced by epithelial and endothelial cells, IL-3 secreted by activated T cells and mast cells is also known for inducing priming of basophils.<sup>17,33-36</sup> We sought to confirm whether human basophil priming by IL-33 at a dose equivalent of that induced by IVIG in patients with rheumatic and neurological autoimmune diseases<sup>11,12</sup> would stimulate IL-4 production as proposed from mouse studies. IL-33 indeed primed human basophils (based on the expression of CD69) and induced IL-4,<sup>37</sup> but the extent of priming was only marginal when compared to IL-3-mediated priming.<sup>17,19</sup> This marginal activation by IL-33 might be also due to the expression pattern of IL-33R as only 22.4±6.3% (n=8) basophils in steady-state express this receptor.

We investigated if IVIG could activate IL-33-primed basophils. However, IVIG did neither modify phenotype nor cytokine production in IL-33-primed basophils. In addition to IL-33, activated epithelial cells also release IL-25 and TSLP.<sup>38</sup> However, basophils were not sensitive for both these cytokines. A recent report also confirms that TSLP does not

activate human basophils.<sup>39</sup> GM-CSF on the other hand, significantly activated human basophils,<sup>40,41</sup> but the extent of activation was lesser than IL-3. Also, GM-CSF-priming had no consequence on IVIG-induced basophil activation.

Noticeably however, IL-3-priming licensed human basophils to undergo activation by IVIG. Rather than IL-33-mediated pathway of basophil IL-4 induction as suggested from the mouse studies, our data suggest an IL-3-mediated pathway of human basophil priming that enables them to directly respond to IVIG by secreting IL-4 (and other cytokines). Although IL-3 significantly enhanced the expression of IL-33R on the basophils, IL-33 did not potentiate IVIG-induced basophil activation when used in combination with IL-3. These data suggest that IL-3 is a major stimulator of basophil functions and could regulate basophil response to IL-33 (probably at higher concentrations as reported earlier<sup>37</sup>) by enhancing the IL-33R expression. In fact, under IL-3-stimulation conditions, CD69 and IL-33R were co-expressed on the basophils. However, this was not the case under IL-33-stimulation conditions, wherein only a minor population of basophils co-expressed CD69 and IL-33R possibly because of marginal stimulation of basophils by IL-33 or IL-33R internalization. All our experiments in this report rely on *in vitro* stimulation system and hence it is important to prove these data in the context of systemic autoimmune and inflammatory diseases. Although data are preliminary, basophil activation also occurs *in vivo* in IVIG-treated myopathy patients. Further analyses of basophils in the inflamed tissues and secondary lymphoid organs should provide more insight on the regulation of basophil functions by IVIG.

Various studies reported that FcγRIIB plays an important role in mediating the anti-inflammatory actions of IVIG. The enhanced expression of FcγRIIB by IVIG has been proposed to increase the threshold level for the activation of innate cells by immune complexes.<sup>22,42-44</sup> However, the absolute requirement of FcγRIIB in mediating anti-

inflammatory actions of IVIG could not be confirmed in other experimental models.<sup>45-48</sup>

Also, several effects of IVIG on human DCs, macrophages and CD4<sup>+</sup> T cells were FcγRIIB-independent.<sup>49-52</sup> Our current data on the basophils provide yet another evidence for FcγRII-independent action of IVIG on human cells.

Several targets and receptors have been identified for IVIG. In addition to the F(ab')<sub>2</sub>-mediated recognition of various self-molecules like HLA, Fas, CD40, Siglecs, BAFF, immunoglobulins and others,<sup>53-59</sup> Fc-α(2,6)-sialic acid-linkages were reported to be recognized by type II Fc receptors, Siglec-2 and DCIR.<sup>13,16,60,61</sup> However, human immune cells display wide variations in the expression pattern of these receptors. In vitro-generated monocyte-derived DCs (equivalent of inflammatory DCs) express both DC-SIGN and DCIR while DCs ex vivo express mainly DCIR.<sup>62</sup> Although CD23 is expressed by B cells, macrophages and eosinophils, Siglec-2 is restricted to B cells. Human basophils, however, lack DC-SIGN, CD23 and Siglec-2. Despite positive for DCIR, resting basophils were not modified by IVIG, suggesting that DCIR is not sufficient (or predominant) in mediating basophil activation by IVIG. Also, other Siglecs that could recognize α(2,6)-sialic acid-linkages were absent on the basophils.

IVIG-induced activation of IL-3-primed human basophils did not lead to degranulation and was distinct to the effect of anti-IgE antibodies identified in the asthmatic patients that induced high expression of degranulation marker CD63.<sup>63</sup> It is possible that the anti-IgE content in IVIG is too low to activate fully basophils to degranulate. Supporting this assumption, antigens at low concentrations have been reported to induce FcεRI-mediated activation of mast cells without causing degranulation.<sup>64,65</sup>

Glycosylation patterns of Fc-domains of IgG determine their engagement with classical type I FcRs (that include FcγRs) or with type II FcRs. The sialylated or non-sialylated

glycans-mediated ‘closed’ vs ‘open’ conformation of Fc, switches engagement of Fc-domain towards type II or type I FcRs respectively.<sup>66</sup> Previous report showed that anti-IgE rabbit IgG inhibit basophil activation by co-engaging with FcγRIIB.<sup>21</sup> However, contrary to this, we observed activation of basophils by anti-IgE IgG present in IVIG. Also, FcγRII-blockade had no significant effect on IVIG-induced basophil activation. Based on all these arguments, we could infer that glycosylation content of Fc-domains of anti-IgE IgG in IVIG is enriched for sialylation that might have prevented engagement of Fc with FcγRII on basophils.

Basophils are implicated in the pathogenesis of chronic urticaria. The anti-IgE or anti-FcεRI autoantibodies in these patients trigger activation and degranulation of basophils.<sup>67</sup> IVIG is reported to be beneficial in such patients.<sup>68</sup> However, our preliminary data suggest that IVIG might not prevent degranulation of basophils and hence the efficacy of IVIG in chronic urticaria patients with anti-IgE or anti-FcεRI autoantibodies might be because of basophil-independent mechanisms. In fact, suppressive effect of IVIG on IgE production by B cells has been reported.<sup>69</sup>

Syk phosphorylation is one of the early signaling events in basophils following IL-3 as well as FcεRI-mediated activation.<sup>17,24,25</sup> Therefore, it is difficult to segregate the importance of IL-3-induced versus FcεRI-induced Syk activation. As IVIG could induce basophil activation only upon IL-3-priming suggests that IL-3-induced Syk phosphorylation is indispensable for basophil FcεRI-bound IgE-mediated activation by IVIG. Syk inhibitor R406 that is proposed for human pathologies<sup>70</sup> blocked IVIG-induced human basophil activation; thus it appears that both “classical” high-affinity IgE-induced degranulation events and IVIG’s anti-IgE activation (without degranulation) events use Syk for signal transduction.

426 To conclude, our report highlights a novel mechanism of activation of human basophils by  
427 IVIG and underlines discrepancies in the mechanisms of action of IVIG in humans and  
428 mice.

429

430 **ACKNOWLEDGMENTS**

431 We thank M Sharma, C Saha, VK Sharma, N Rambabu and the staff of Centre  
432 d'Histologie, d'Imagerie et de Cytométrie, Centre de Recherche des Cordeliers for the help;  
433 and F. Carrère at Royan Hospital for sending the IgE myeloma serum.

434

435

436

## REFERENCES

1. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J Allergy Clin Immunol*. 2017; 139:S1-S46.
2. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. *N Engl J Med*. 2012; 367:2015-25.
3. Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. *CMAJ*. 2015; 187:257-64.
4. Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. *Nat Rev Neurol* 2015; 11:80-9.
5. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat Rev Immunol* 2013; 13:176-89.
6. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. *Int Immunol* 2017; 29:491-8.
7. Schroeder JT. Basophils: emerging roles in the pathogenesis of allergic disease. *Immunol Rev* 2011; 242:144-60.
8. Karasuyama H, Miyake K, Yoshikawa S, Yamanishi Y. Multifaceted roles of basophils in health and disease. *J Allergy Clin Immunol* 2018; 142: 370-80.
9. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. *Nature*. 2011; 475:110-3.
10. Egawa M, Mukai K, Yoshikawa S, Iki M, Mukaida N, Kawano Y, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. *Immunity* 2013; 38:570-80.

- 461        11.     Sharma M, Schoindre Y, Hegde P, Saha C, Maddur MS, Stephen-Victor E, et  
462                al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate  
463                basophil expansion in autoimmune patients. *Sci Rep* 2014; 4:5672.
- 464        12.     Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, et al.  
465                Regulatory T cell frequency, but not plasma IL-33 levels, represents potential  
466                immunological biomarker to predict clinical response to intravenous  
467                immunoglobulin therapy. *J Neuroinflammation* 2017; 14: 58.
- 468        13.     Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and  
469                T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires  
470                type II FcRs. *Proc Natl Acad Sci U S A* 2015; 112:E2385-94.
- 471        14.     Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J. Human  
472                basophils may not undergo modulation by DC-SIGN and mannose receptor-  
473                targeting immunotherapies due to absence of receptors. *J Allergy Clin Immunol*  
474                2017; 139:1403-4.
- 475        15.     Nutku E, Aizawa H, Lim L, Tashimoto H, Hudson S, Crocker P, et al.  
476                Expression of CD33-Related siglecs on human eosinophils, basophils and  
477                mast Cells. *J Allergy Clin Immunol* 2004; 113:S84
- 478        16.     Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al.  
479                Dendritic cell immunoreceptor: a novel receptor for intravenous  
480                immunoglobulin mediates induction of regulatory T cells. *J Allergy Clin*  
481                *Immunol* 2014; 133:853-63.
- 482        17.     Voehringer D. Basophil modulation by cytokine instruction. *Eur J Immunol*  
483                2012; 42:2544-50.

18. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. *J Exp Med* 1993; 177:605-11.
19. Yoshimura C, Yamaguchi M, Iikura M, Izumi S, Kudo K, Nagase H, et al. Activation markers of human basophils: CD69 expression is strongly and preferentially induced by IL-3. *J Allergy Clin Immunol* 2002; 109:817-23.
20. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* 2008; 8:34-47.
21. Cassard L, Jonsson F, Arnaud S, Daeron M. Fcγ receptors inhibit mouse and human basophil activation. *J Immunol* 2012; 189:2995-3006.
22. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. *Proc Natl Acad Sci U S A* 2009; 106:4788-92.
23. Audia S, Santegoets K, Laarhoven AG, Vidarsson G, Facy O, Ortega-Deballon P, et al. Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. *Clin Exp Immunol* 2017; 188:275-82.
24. Hida S, Yamasaki S, Sakamoto Y, Takamoto M, Obata K, Takai T, et al. Fc receptor gamma-chain, a constitutive component of the IL-3 receptor, is required for IL-3-induced IL-4 production in basophils. *Nat Immunol* 2009;10:214-22.
25. Siraganian RP, de Castro RO, Barbu EA, Zhang J. Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. *FEBS Lett* 2010;584:4933-40.

26. Sharma M, Bayry J. Autoimmunity: Basophils in autoimmune and inflammatory diseases. *Nat Rev Rheumatol* 2015;11:129-31.
27. Pellefigues C, Dema B, Lamri Y, Saidoune F, Chavarot N, Lohéac C, et al. Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs. *Nat Commun* 2018; 9:725.
28. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. *J Immunol* 2014;192:5031-8.
29. Hammad H, Plantinga M, Deswarte K, Pouliot P, Willart MA, Kool M, et al. Inflammatory dendritic cells--not basophils--are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. *J Exp Med* 2010; 207:2097-111.
30. Phythian-Adams AT, Cook PC, Lundie RJ, Jones LH, Smith KA, Barr TA, et al. CD11c depletion severely disrupts Th2 induction and development in vivo. *J Exp Med* 2010;207:2089-96.
31. Stephen-Victor E, Das M, Sharma M, Galeotti C, Fohrer-Ting H, Sendid B, et al. Demystification of enigma on antigen-presenting cell features of human basophils: data from secondary lymphoid organs. *Haematologica* 2017; 102, e233-e37.
32. Miyake K, Shiozawa N, Nagao T, Yoshikawa S, Yamanishi Y, Karasuyama H. Trogocytosis of peptide-MHC class II complexes from dendritic cells confers antigen-presenting ability on basophils. *Proc Natl Acad Sci U S A* 2017; 114: 1111-16.

- 532        33.    Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA.  
533            Human basophils and eosinophils are the direct target leukocytes of the novel  
534            IL-1 family member IL-33. *Blood* 2009;113:1526-34.
- 535        34.    Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE.  
536            IL-33 amplifies both Th1- and Th2-type responses through its activity on  
537            human basophils, allergen-reactive Th2 cells, iNKT and NK cells. *Int Immunol*  
538            2008; 20:1019-30.
- 539        35.    Leyva-Castillo JM, Hener P, Michea P, Karasuyama H, Chan S, Soumelis V, et  
540            al. Skin thymic stromal lymphopoietin initiates Th2 responses through an  
541            orchestrated immune cascade. *Nat Commun* 2013;4:2847.
- 542        36.    Sharma M, Das M, Stephen-Victor E, Galeotti C, Karnam A, Maddur MS, et al.  
543            Regulatory T cells induce activation rather than suppression of human  
544            basophils. *Sci Immunol* 2018; 3: eaan0829.
- 545        37.    Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An  
546            IL-1 cytokine member, IL-33, induces human basophil activation via its ST2  
547            receptor. *J Immunol* 2008; 181: 5981-89.
- 548        38.    Strickland DH, Upham JW, Holt PG. Epithelial-dendritic cell interactions in  
549            allergic disorders. *Curr Opin Immunol* 2010; 22: 789-94.
- 550        39.    Salabert-Le Guen N, Hémont C, Delbove A, Poli C, Braudeau C, Fantou A, et  
551            al. Thymic stromal lymphopoietin does not activate human basophils. *J Allergy*  
552            *Clin Immunol* 2018; 141: 1476-79.
- 553        40.    Tedeschi A, Salmaso C, Di Donato M, Lorini M, Miadonna A. Granulocyte-  
554            macrophage colony-stimulating factor and interleukin-3 cause basophil  
555            histamine release by a common pathway: downregulation by sodium.  
556            *Immunology* 1999; 96: 164-70.

41. Bischoff SC, de Weck AL, Dahinden CA. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. *Proc Natl Acad Sci U S A* 1990; 87: 6813-17.
42. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. *Science* 2001; 291:484-6.
43. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. *Immunity* 2003;18:573-81.
44. Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. *Eur J Immunol* 2014;44:1444-53.
45. Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP. *Blood* 2012;119:5261-4.
46. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. *Blood* 2012;119:3084-96.
47. Othy S, Hegde P, Topcu S, Sharma M, Maddur MS, Lacroix-Desmazes S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. *J Immunol* 2013;190:4535-41.

48. Crow AR, Lazarus AH. Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for Fc $\gamma$ RIIB falls by the wayside. *Semin Hematol* 2016;53:S20-2.
49. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. *J Allergy Clin Immunol* 2011;127:823-30.
50. Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of Fc $\gamma$ R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc $\gamma$ RIIb in human macrophages. *Blood* 2014;124:3709-18.
51. Wiedeman AE, Santer DM, Yan W, Miescher S, Kasermann F, Elkon KB. Contrasting mechanisms of interferon- $\alpha$  inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. *Arthritis Rheum* 2013;65:2713-23.
52. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. *Blood* 2013;122:1419-27.
53. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. *Proc Natl Acad Sci U S A* 2004;101:14210-5.
54. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. *Int Immunol* 2007;19:857-65.

55. Le Pottier L, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. *J Clin Immunol* 2007;27:257-65.
56. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. *J Immunol* 1998;161:3781-90.
57. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. *Int Immunol* 2002;14:1303-11.
58. von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. *J Allergy Clin Immunol* 2007;119:1005-11.
59. Schneider C, Wicki S, Graeter S, Timcheva TM, Keller CW, Quast I, et al. IVIG regulates the survival of human but not mouse neutrophils. *Sci Rep* 2017;7:1296.
60. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc Natl Acad Sci U S A* 2008;105:19571-8.
61. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. *Blood* 2010;116:1698-704.
62. Lundberg K, Albrekt AS, Nelissen I, Santegoets S, de Gruijl TD, Gibbs S, et al. Transcriptional profiling of human dendritic cell populations and models--

- 631 unique profiles of in vitro dendritic cells and implications on functionality and  
 632 applicability. PLoS One 2013;8:e52875.
- 633 63. Chan YC, Ramadani F, Santos AF, Pillai P, Ohm-Laursen L, Harper CE, et al.  
 634 Auto-anti-IgE: naturally occurring IgG anti-IgE antibodies may inhibit allergen-  
 635 induced basophil activation. J Allergy Clin Immunol 2014;134:1394-401.
- 636 64. Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-  
 637 Dos-Santos A, et al. Preferential signaling and induction of allergy-promoting  
 638 lymphokines upon weak stimulation of the high affinity IgE receptor on mast  
 639 cells. J Exp Med 2003;197:1453-65.
- 640 65. Grodzki AC, Moon KD, Berenstein EH, Siraganian RP. FcεRI-induced  
 641 activation by low antigen concentrations results in nuclear signals in the  
 642 absence of degranulation. Mol Immunol 2009;46:2539-47.
- 643 66. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al.  
 644 Type I and type II Fc receptors regulate innate and adaptive immunity. Nat  
 645 Immunol 2014; 15: 707-16.
- 646 67. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy  
 647 2009; 39: 777-87.
- 648 68. Amar SM, Harbeck RJ, Dreskin SC. Effect of Intravenous immunoglobulin in  
 649 chronic urticaria with increased basophil CD203c expression. J Allergy Clin  
 650 Immunol 2008; 121: S98.
- 651 69. Zhuang Q, Mazer B. Inhibition of IgE production in vitro by intact and  
 652 fragmented intravenous immunoglobulin. J Allergy Clin Immunol 2001; 108:  
 653 229-34.
- 654 70. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406,  
 655 an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling

656 and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther  
657 2006; 319:998-1008.  
658

**FIGURE LEGENDS**

**FIG 1.** IVIG induces activation and cytokine secretion in IL-3-primed basophils. **A-C**, Isolated basophils from the human circulation were cultured either alone or with IVIG. (A and B) Representative dot plots and expression (% positive cells and mean fluorescence intensity (MFI)) of CD69 on the basophils (mean $\pm$ SEM, n=6 donors). (C) Amount of secretion of IL-4, IL-6 and IL-8 (mean $\pm$ SEM, n=5 donors). ns, not significant, two-tailed Mann-Whitney test. **D-F**, Basophils were cultured either alone or with IL-3. IVIG or HSA were added following 2 hours stimulation with IL-3. (D) Representative histogram overlays and MFI of CD69 expression on the basophils (mean $\pm$ SEM, n=10 donors), (E) Representative dot plots and % of basophils (mean $\pm$ SEM, n=4 donors) positive for CD63, (F) Effect of IVIG on the secretion (pg/ml) of IL-4, IL-6 and IL-8 (mean $\pm$ SEM, n=12 donors) by IL-3-primed basophils. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests. **G**, Expression of CD69 on the basophils of myopathy patients, before (Pre-IVIG) and Post-IVIG therapy.

**FIG 2.** IL-33 is dispensable for the activation of human basophils by IVIG. Basophils were cultured either alone or with IL-33. IVIG or HSA were added following 2 hours stimulation with IL-33. **A and B**, Representative dot plots and expression (% positive cells and MFI) of CD69 on the basophils (mean $\pm$ SEM, n=6 donors). **C**, Amount of secretion of IL-4 and IL-8 (mean $\pm$ SEM, n=6 donors). **D and E**, basophils were stimulated with IL-3 for one hour followed by IL-33 for additional hour before culturing with IVIG or HSA. (D) Expression (% positive cells and MFI) of CD69 on the basophils. (E) Amount of secretion of IL-4 and IL-8 (mean $\pm$ SEM, n=4 donors) \*\*\*P<0.001; \*\*\*\*P<0.0001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.

683

684 **FIG 3.** Expression of type II FcRs, Siglecs and C-type lectin receptors on basophils, and  
 685 the effects of F(ab')<sub>2</sub>- and Fc-fragments of IVIG on basophil activation. **A and B,**  
 686 Representative dot plots of CD23 and CD22 expression on the basophils. **C and D,**  
 687 Representative dot plots and expression (% positive cells and MFI) of DCIR on the  
 688 basophils (mean±SEM, n=3 donors). **E-H,** Basophils were cultured either alone or with IL-  
 689 3 for 24 hours. IVIG, F(ab')<sub>2</sub> or Fc-fragments were added following 2 hours stimulation  
 690 with IL-3. (E and F) The expression of CD69 (mean±SEM, n=6 donors). (G and H) The  
 691 amount of secretion of IL-4, and IL-8 (mean±SEM, n=4-5 donors). \*P<0.05; \*\*P<0.01;  
 692 \*\*\*P<0.001; \*\*\*\*P<0.001; ns, not significant, one-way ANOVA with Tukey's multiple  
 693 comparison tests.


694


695 **FIG 4.** Basophil activation by IVIG is mediated by a fraction of IgG that signals through  
 696 basophil FcεRI-bound IgE. **A and B,** Modulation of FcεRI expression (Representative  
 697 histogram overlays and mean±SEM, n=10 donors) in IL-3-primed basophils by IVIG. **C,**  
 698 Representative dot plots showing the basophils positive for surface IgE. **D,** Percentage of  
 699 basophils positive for the surface IgE and its intensity (MFI) (mean±SEM, n=5 donors). **E**  
 700 **and F,** Percentage of basophils positive for IVIG-binding (Representative dot plots and  
 701 mean±SEM, n=4 donors). **G-I,** The effect of anti-IgE-reactivity-depleted IVIG on (G, H)  
 702 the expression of CD69 (Representative histogram overlays and mean±SEM, n=4 donors)  
 703 and (I) IL-4, and IL-8 secretion (mean±SEM, n=4 donors). \*P<0.05; \*\*P<0.01;  
 704 \*\*\*P<0.001; \*\*\*\*P<0.0001; ns, not significant, two-tailed Mann-Whitney test or one-way  
 705 ANOVA with Tukey's multiple comparison tests.


706


**FIG 5.** Activating and inhibitory CD32/FcγRII are dispensable for the regulation of basophil activation by IVIG. Basophils were cultured either alone or with IL-3 for 24 hours. IVIG or HSA were added following 2 hours stimulation with IL-3. **A and B**, Representative histogram overlays and mean fluorescence intensity (MFI) of expression (mean±SEM, n=8 donors) of FcγRII and FcγRIIB on the basophils. **C and D**, Repercussion of FcγRIIB blockade on the (C) expression of CD69 and (D) amount of IL-4 and IL-8 secretion (mean±SEM, n=8 donors). **E and F**, Repercussion of FcγRIIA blockade on the (E) expression of CD69 and (F) amount of IL-4 and IL-8 secretion (mean±SEM, n=4 donors). \*P<0.05; \*\*P<0.001; \*\*\*P<0.001; \*\*\*\*P<0.0001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.


**FIG 6.** Inhibition of Syk pathway abrogates IVIG-induced activation of basophils. **A and B**, Representative histogram overlays and mean±SEM (n=6 donors) of phosphorylated Syk (pSyk) expression in basophils stimulated with IL-3 or IL-3 plus IVIG. **C and D**, The effect of Syk inhibition by R406 towards IVIG-induced expression of CD69 (Representative histogram overlays and mean±SEM, n=5 donors). **E**, Syk inhibition abrogates IVIG-induced IL-4, and IL-8 secretion (mean±SEM, n=4 donors). \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.














**Online Repository**

**Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE**

**Caroline Galeotti, MD, PhD<sup>1,2</sup>, Emmanuel Stephen-Victor, PhD<sup>1,\*</sup>, Anupama Karnam, MSc<sup>1,\*</sup>, Mrinmoy Das, PhD<sup>1</sup>, Laurent Gilardin, MD<sup>1,3</sup>, Mohan S Maddur, DVM, PhD<sup>1,4</sup>, Sandra Wymann, PhD<sup>5</sup>, Cédric Vonarburg, PhD<sup>5</sup>, Alain Chevailler, MD, PhD<sup>6</sup>, Jordan D Dimitrov, PhD<sup>1,4</sup>, Olivier Benveniste, MD<sup>3,7</sup>, Pierre Bruhns, PhD<sup>8,9</sup>, Srini V Kaveri, DVM, PhD<sup>1,4</sup>, Jagadeesh Bayry, DVM, PhD<sup>1,4</sup>**

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale; Centre de Recherche des Cordeliers, Equipe- Immunopathologie et Immunointervention Thérapeutique; Sorbonne Université, Paris, F-75006, France

<sup>2</sup>Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires rares et des Amyloses, CHU de Bicêtre, le Kremlin Bicêtre, F-94270, France

<sup>3</sup> Département de Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, F-75013, France.

<sup>4</sup>Université Paris Descartes, Sorbonne Paris Cité, Paris, F-75006, France

<sup>5</sup>Research Department, CSL Behring AG, 3014 Bern, Switzerland

<sup>6</sup>Laboratoire d'Immunologie et d'Allergologie; CHU d'Angers; Université d'Angers; INSERM Unité1232; LabEx IGO "Immuno-Graft-Onco", Angers, F-49933, France

<sup>7</sup>Sorbonne Université, Institut National de la Santé et de la Recherche Médicale Unité 974, Paris, F-75013, France.

<sup>8</sup>Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France

<sup>9</sup> INSERM, Unité 1222, Paris, France

\* Equally contributed

**Correspondence to:** Jagadeesh Bayry, Institut National de la Santé et de la Recherche  
Médicale Unité 1138, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Médecine,  
Paris, F-75006, France. Tel: 00 33 1 44 27 82 03 ; Fax: 00 33 1 44 27 81 94  
E-mail: [jagadeesh.bayry@crc.jussieu.fr](mailto:jagadeesh.bayry@crc.jussieu.fr)

**Total word count: 134**

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71

## METHODS

### List of antibodies for flow cytometry and functional assays

CD63-PE (Clone:H5C6), CD13-APC (Clone:WM15), CD123-BV421 (Clone:9F5), CD69-APC/Cy7 (Clone:FN50), CD209-APC (Clone:DCN46), CD22-PE (Clone:S-HCL-1) and CD62L-FITC (Clone:DREG-56) were from BD Biosciences. FcεRIα-FITC (Clone:CRA-1), SIGLEC3-FITC (Clone:AC104.3E3), SIGLEC5-FITC (Clone:1A5), SIGLEC7-FITC (Clone:REA214), SIGLEC8-APC (Clone:7C9), anti-IgE-APC (clone:MB10-5C4) MAbs were obtained from Miltenyi Biotec. CD203c-PE (Clone:NP4D6), CD23-PE (Clone:B3B4), CD107a-BV421 (Clone:H4A3), FcεRIα-BV510 (Clone:AER37 [CRA-1]) and DCIR-PE (Clone:9E8) MAbs were from BioLegend. Anti-IgE MAb (Clone:GE-1) was from Sigma Aldrich. Unconjugated and FITC-labelled FcγRIIA MAb (Clone:IV.3) was purchased from Stem Cells Technologies. Human ST2/IL-33R-PE polyclonal goat IgG and Isotype control MAbs for blocking experiments were from R&D Systems. Anti-human p-Syk (Tyr348) (clone: moch1ct) was from eBioscience. Anti-hFcγRIIB (Clone:2B6 variant N<sub>297</sub>D) MAbs were coupled to Alexa Fluor 647 by using ThermoFisher Scientific kit and IVIG was labelled with the Lightning-Link® Rapid DyLight® 650 kit (Innova Biosciences).

## Supplementary Figure Legends

**FIG E1.** Effect of IVIG on the expression of various surface markers in IL-3-primed basophils. **A and B,** Basophils were cultured either alone or with IL-3. IVIG or HSA were added following 2 hours stimulation with IL-3. (A) Representative histogram overlays and (B), expression (mean±SEM, n=4-12 donors) of CD69, CD13 (both in % positive cells), CD62L, CD123 and CD203c (all MFI) on the basophils. \*P<0.05; \*\*\*P<0.001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.

**FIG E2.** Activation of IL-3-primed basophils by IVIG is not associated with degranulation. **A and B,** Changes in the expression of CD107a. Representative plots and mean±SEM of data from four independent donors. **C,** Amount of histamine in the culture supernatants (mean±SEM, n=5 donors). ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.

**FIG E3. A and B.** Real-time quantitative RT-PCR analysis of *il4* transcripts and amount of IL-4 secretion in resting basophils, cells treated with IL-3 or IL-3 plus IVIG for three hours. \*P<0.05; \*\*P<0.05; ns, not significant, one-way ANOVA (with Dunnet's (for Panel A) or Tukey's (for Panel B) multiple comparison tests).

**FIG E4.** The expression of IL-33R (% positive cells and MFI) on resting, IL-33- or IL-3-stimulated basophils (mean±SEM, n=8 donors). \*P<0.05; \*\*P<0.01; \*\*\*\*P<0.0001; ns, not significant, one-way ANOVA with Tukey's multiple comparison tests.

94


95 **FIG E5.** IL-25, TSLP and GM-CSF are dispensable for the activation of basophils by IVIG  
 96 **A-C,** Basophils were cultured either alone or with (A) IL-25, (B) TSLP or (C) GM-CSF for  
 97 24 hours. IVIG was added following 2 hours stimulation with respective cytokines. The  
 98 expression of CD69 (% positive cells or MFI) and the amount of secretion of IL-4  
 99 (mean±SEM, n=5 donors) are presented. \*P<0.05; \*\*P<0.01; ns, not significant, one-way  
 100 ANOVA with Tukey's multiple comparison tests.




101

102 **FIG E6. A-B,** The expression of (A) Siglec-3 and Siglec-5/14; (B) Siglec-7 and Siglec-8 on  
 103 resting and IL-3-primed basophils.


104

105 **FIG E7:** The effect of Syk inhibition towards IVIG-induced expression of *il4* transcripts  
 106 (mean±SEM, n=5 donors). Basophils were stimulated with IL-3 plus IVIG for three hours.  
 107 Additionally, cells were also treated with syk inhibitor R406 for one hour prior to stimulation  
 108 with IL-3 plus IVIG. \*P<0.05; two-tailed Mann-Whitney test.









**A**




**B**









**A**



**B**





Intravenous immunoglobulin (IVIg) activates human basophils through direct interaction with surface-bound IgE, and by IL-3- and Syk-dependent mechanisms

